Scientists may have found a way to prevent statin muscle pain

Millions of individuals take statins to lower cholesterol and lower their risk of heart attack or stroke. Unfortunately, some patients encounter muscle pain, weakness, and difficulty exercising due to the medication, which can deter them from continuing treatment. Researchers at McMaster University have discovered a biological pathway that may clarify why these muscle symptoms manifest, potentially paving the way for treatments that make statins easier to tolerate while preserving their crucial cardiovascular benefits.

The study, published in Science Advances, highlights an uncharted interaction between the immune system and muscle cell metabolism, contributing to muscle damage caused by statins and contradicting previous notions about these side effects' origins. Statins are among the most efficient drugs in reducing cardiovascular disease risk and preventing early death, according to Jonathan Schertzer, a professor at McMaster's Department of Biochemistry and Biomedical Sciences and the study's senior author.

However, muscle side effects prompt some people to lower their dose or discontinue the medication altogether. The researchers aimed to comprehend why this occurs and whether it might be possible to separate the side effects from the benefits. Approximately seven to 29 percent of statin users experience muscle-related symptoms. While the link between statins and muscle problems has been acknowledged for years, scientists have not comprehensively understood the underlying biological mechanisms.

Led by first authors Nazli Robin and Nicole Barra from the Schertzer Lab at McMaster, the team discovered that statins interfere with muscle cells' energy generation process. This disruption appears to trigger an immune response within the muscle cells, resulting in tissue damage. Experiments with muscle cells and mouse models revealed that preventing the immune response could significantly reduce much of the damage.

One of the most exciting findings is that the mechanism causing muscle side effects appears to be distinct from the mechanism that lowers cholesterol, suggesting that it may one day be possible to target the side effects without interfering with the cholesterol-lowering benefits that make statins so valuable. The research also unveiled an unexpected connection between metabolism and the immune system.

Muscle cells' altered energy processing prompted the cells to activate their own immune response, offering new insight into how inflammation might contribute to medication side effects. This discovery implies that scientists could potentially protect muscle tissue by targeting the immune pathway while maintaining statins' cholesterol-lowering effects.

Further research is necessary before the findings can be translated into treatments for patients. Nonetheless, the newly identified pathway provides several potential targets for medications designed to prevent statin intolerance. These findings enhance our understanding of why some patients experience muscle symptoms and offer promising avenues for making these critical medications safer and more effective in the future.